 AIM ImmunoTech Inc NYSE: AIM has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial HCT for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT will test Ampligen as a potential intranasal prophylactic using a human rhinovirus HRV-16, a common cold virus and influenza A virus H3N2. 